Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant

摘要

Biosimilar filgrastim was compared with lenograstim for autologous haematopoietic stem-cell transplant (HSCT) in patients with haematological malignancies. Data from a separate group of sibling donors who underwent allogeneic HSCT are also reported. Patients with lymphoma or multiple myeloma (MM) who underwent autologous HSCT with biosimilar filgrastim were compared with a historical control group of patients who received lenograstim. Peripheral blood (PB) cells counts were monitored after 7–8 consecutive days of granulocyte-colony stimulating factor (G-CSF) injection and apheresis was performed on day 8 if PB CD34+ cell count was ?10?cells/μl. The target PB CD34+ cell doses were ?2.0?×?106/kg (lymphoma), ?4.0?×?106/kg (MM ?60 years old) or ?8.0?×?106/kg (MM A total of 259 patients were included in the autologous HSCT comparison (biosimilar filgrastim, n?=?104; lenograstim, n?=?155). In patients with lymphoma and older MM patients (?60 years old), no significant differences were observed between groups with regard to stem-cell mobilization parameters. However, in MM patients 6/kg. A total of 13 donors needed a second apheresis and 4 required a third. Among recipients, median days to ANC recovery was 16 (10–28) and to platelet recovery was 13 (9–54). Biosimilar filgrastim is as effective as lenograstim for autologous HSCT in patients with lymphoma or MM patients ?60 years old. However, mobilization with biosimilar filgrastim appeared to be superior to that with lenograstim in younger MM patients.